{"id": "article-35928_0", "title": "Tobramycin -- Continuing Education Activity", "content": "Tobramycin is an effective antibiotic commonly used in the management and treatment of various systemic and ocular infections. As an aminoglycoside antibiotic, tobramycin is active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Due to its broad spectrum of activity, tobramycin is prescribed for the treatment of both superficial and deep infections. This activity provides a comprehensive review of the indications, mechanisms of action, potential toxicities, off-label uses, dosing considerations, pharmacodynamics, pharmacokinetics, monitoring requirements, and relevant drug interactions associated with tobramycin to assist the healthcare team in decision-making and optimal patient care.", "contents": "Tobramycin -- Continuing Education Activity. Tobramycin is an effective antibiotic commonly used in the management and treatment of various systemic and ocular infections. As an aminoglycoside antibiotic, tobramycin is active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Due to its broad spectrum of activity, tobramycin is prescribed for the treatment of both superficial and deep infections. This activity provides a comprehensive review of the indications, mechanisms of action, potential toxicities, off-label uses, dosing considerations, pharmacodynamics, pharmacokinetics, monitoring requirements, and relevant drug interactions associated with tobramycin to assist the healthcare team in decision-making and optimal patient care."}
{"id": "article-35928_1", "title": "Tobramycin -- Continuing Education Activity", "content": "Objectives: Identify the appropriate indications for tobramycin therapy in the treatment of various infections. Apply evidence-based guidelines and recommendations when selecting tobramycin as a treatment option. Assess patients for potential adverse effects and monitor for signs of nephrotoxicity and ototoxicity during tobramycin therapy. Collaborate with infectious disease specialists, pharmacists, and other healthcare team members to optimize tobramycin therapy and ensure patient safety. Access free multiple choice questions on this topic.", "contents": "Tobramycin -- Continuing Education Activity. Objectives: Identify the appropriate indications for tobramycin therapy in the treatment of various infections. Apply evidence-based guidelines and recommendations when selecting tobramycin as a treatment option. Assess patients for potential adverse effects and monitor for signs of nephrotoxicity and ototoxicity during tobramycin therapy. Collaborate with infectious disease specialists, pharmacists, and other healthcare team members to optimize tobramycin therapy and ensure patient safety. Access free multiple choice questions on this topic."}
{"id": "article-35928_2", "title": "Tobramycin -- Indications", "content": "Tobramycin belongs to the class of broad-spectrum antibiotics known as aminoglycosides. Streptomycin,\u00a0the first aminoglycoside,\u00a0was first isolated from Streptomyces griseus and introduced into clinical use in 1944; this led to the\u00a0successful development of others in its category. [1] The majority of antibiotics in this class, including tobramycin, are bactericidal. [2]", "contents": "Tobramycin -- Indications. Tobramycin belongs to the class of broad-spectrum antibiotics known as aminoglycosides. Streptomycin,\u00a0the first aminoglycoside,\u00a0was first isolated from Streptomyces griseus and introduced into clinical use in 1944; this led to the\u00a0successful development of others in its category. [1] The majority of antibiotics in this class, including tobramycin, are bactericidal. [2]"}
{"id": "article-35928_3", "title": "Tobramycin -- Indications", "content": "These drugs work synergistically with beta-lactams to penetrate the cell walls of aerobic gram-negative bacteria. [3] Aminoglycosides are then actively transported across the bacterial cell membrane to bind and inactivate\u00a0the initiation complex of translation. [4] Tobramycin has been\u00a0prescribed to treat superficial infections and deep infections. [5]", "contents": "Tobramycin -- Indications. These drugs work synergistically with beta-lactams to penetrate the cell walls of aerobic gram-negative bacteria. [3] Aminoglycosides are then actively transported across the bacterial cell membrane to bind and inactivate\u00a0the initiation complex of translation. [4] Tobramycin has been\u00a0prescribed to treat superficial infections and deep infections. [5]"}
{"id": "article-35928_4", "title": "Tobramycin -- Indications -- Indications", "content": "The FDA has approved systemic administration (intramuscular or intravenous) of tobramycin to treat various reinfections caused by susceptible organisms,\u00a0mainly gram-negative bacteria and Staphylococcus aureus (penicillinase and non\u00ad penicillinase-producing strains). Gram-negative bacteria include Pseudomonas aeruginosa , Escherichia coli, and species of Proteus, Klebsiella, Enterobacter, Serratia, Providencia , and Citrobacter .", "contents": "Tobramycin -- Indications -- Indications. The FDA has approved systemic administration (intramuscular or intravenous) of tobramycin to treat various reinfections caused by susceptible organisms,\u00a0mainly gram-negative bacteria and Staphylococcus aureus (penicillinase and non\u00ad penicillinase-producing strains). Gram-negative bacteria include Pseudomonas aeruginosa , Escherichia coli, and species of Proteus, Klebsiella, Enterobacter, Serratia, Providencia , and Citrobacter ."}
{"id": "article-35928_5", "title": "Tobramycin -- Indications -- Indications", "content": "Infections caused by organisms susceptible to tobramycin can vary in nature and include septicemia, lower respiratory tract infections, central nervous system (CNS) infections like meningitis, intra-abdominal infections, skin and subcutaneous tissue infections, osteomyelitis, and complicated urinary tract infections.", "contents": "Tobramycin -- Indications -- Indications. Infections caused by organisms susceptible to tobramycin can vary in nature and include septicemia, lower respiratory tract infections, central nervous system (CNS) infections like meningitis, intra-abdominal infections, skin and subcutaneous tissue infections, osteomyelitis, and complicated urinary tract infections."}
{"id": "article-35928_6", "title": "Tobramycin -- Indications -- Indications", "content": "Inhaled tobramycin is\u00a0FDA-approved to manage cystic fibrosis (CF) in\u00a0patients aged six or older with Pseudomonas aeruginosa. [6]  CF guidelines recommend the chronic use of inhaled tobramycin in patients with CF to\u00a0improve lung function, reduce exacerbations, and improve quality of life in patients with CF. [7] Tobramycin for ophthalmic use is FDA-approved to treat external ocular infections caused by susceptible organisms in adults and children.", "contents": "Tobramycin -- Indications -- Indications. Inhaled tobramycin is\u00a0FDA-approved to manage cystic fibrosis (CF) in\u00a0patients aged six or older with Pseudomonas aeruginosa. [6]  CF guidelines recommend the chronic use of inhaled tobramycin in patients with CF to\u00a0improve lung function, reduce exacerbations, and improve quality of life in patients with CF. [7] Tobramycin for ophthalmic use is FDA-approved to treat external ocular infections caused by susceptible organisms in adults and children."}
{"id": "article-35928_7", "title": "Tobramycin -- Indications -- Indications", "content": "Off-label use of tobramycin includes intraventricular administration in managing intraventricular catheter-associated central nervous system infections. [8] According to guidelines\u00a0from the\u00a0American Academy of Allergy, Asthma, and Immunology, tobramycin can be used for\u00a0prophylaxis of bacterial respiratory tract infection\u00a0in patients with\u00a0primary immunodeficiency diseases. [9]", "contents": "Tobramycin -- Indications -- Indications. Off-label use of tobramycin includes intraventricular administration in managing intraventricular catheter-associated central nervous system infections. [8] According to guidelines\u00a0from the\u00a0American Academy of Allergy, Asthma, and Immunology, tobramycin can be used for\u00a0prophylaxis of bacterial respiratory tract infection\u00a0in patients with\u00a0primary immunodeficiency diseases. [9]"}
{"id": "article-35928_8", "title": "Tobramycin -- Mechanism of Action", "content": "Tobramycin binds to the 16s ribosomal RNA component of the bacterial 30s ribosomal unit, inhibiting the initiation step of translation. [2] By binding to the A-site, tobramycin induces mistranslation and causes transfer RNA to misread the codon, thus causing incorrect delivery of aminoacyl units. Incorrectly synthesized proteins build up inside the cell, disrupting the cell membrane and various cellular processes; this mechanism of action designates tobramycin as a bactericidal agent. [10] [11]", "contents": "Tobramycin -- Mechanism of Action. Tobramycin binds to the 16s ribosomal RNA component of the bacterial 30s ribosomal unit, inhibiting the initiation step of translation. [2] By binding to the A-site, tobramycin induces mistranslation and causes transfer RNA to misread the codon, thus causing incorrect delivery of aminoacyl units. Incorrectly synthesized proteins build up inside the cell, disrupting the cell membrane and various cellular processes; this mechanism of action designates tobramycin as a bactericidal agent. [10] [11]"}
{"id": "article-35928_9", "title": "Tobramycin -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Tobramycin is absorbed rapidly following intramuscular injection. Peak serum concentrations of tobramycin\u00a0are achieved in 30 to 90 minutes following intramuscular administration. Tobramycin dose of 1 mg/kg of body weight results in 4 mcg/mL peak serum concentrations. Therapeutic levels of tobramycin are generally considered to be between 4 to 6 mcg/mL.", "contents": "Tobramycin -- Mechanism of Action -- Pharmacokinetics. Absorption: Tobramycin is absorbed rapidly following intramuscular injection. Peak serum concentrations of tobramycin\u00a0are achieved in 30 to 90 minutes following intramuscular administration. Tobramycin dose of 1 mg/kg of body weight results in 4 mcg/mL peak serum concentrations. Therapeutic levels of tobramycin are generally considered to be between 4 to 6 mcg/mL."}
{"id": "article-35928_10", "title": "Tobramycin -- Mechanism of Action -- Pharmacokinetics", "content": "When tobramycin is administered via intravenous infusion over one hour, it achieves similar serum concentrations compared to intramuscular administration.\u00a0Tobramycin is poorly absorbed from the gastrointestinal tract. Tobramycin is excreted via the kidneys through glomerular filtration.\u00a0The serum half-life of tobramycin is about 2 hours in an adult and prolonged in neonates to about 4.5\u00a0to 8.7 hours. [12]", "contents": "Tobramycin -- Mechanism of Action -- Pharmacokinetics. When tobramycin is administered via intravenous infusion over one hour, it achieves similar serum concentrations compared to intramuscular administration.\u00a0Tobramycin is poorly absorbed from the gastrointestinal tract. Tobramycin is excreted via the kidneys through glomerular filtration.\u00a0The serum half-life of tobramycin is about 2 hours in an adult and prolonged in neonates to about 4.5\u00a0to 8.7 hours. [12]"}
{"id": "article-35928_11", "title": "Tobramycin -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution:\u00a0Concentrations in bile and stools are low, indicating minimum biliary excretion. Tobramycin is present in CSF, and concentrations depend on the dose and extent of meningeal inflammation. Tobramycin is distributed in sputum, synovial, and peritoneal fluids. It also crosses the placental membranes. Concentrations in the kidney are higher than in the serum. Inhaled tobramycin produces bactericidal concentrations in the lower respiratory tract in children with cystic fibrosis. [13] Metabolism: The uptake\u00a0of tobramycin into hepatocytes is limited, and the drug is minimally metabolized in the liver.", "contents": "Tobramycin -- Mechanism of Action -- Pharmacokinetics. Distribution:\u00a0Concentrations in bile and stools are low, indicating minimum biliary excretion. Tobramycin is present in CSF, and concentrations depend on the dose and extent of meningeal inflammation. Tobramycin is distributed in sputum, synovial, and peritoneal fluids. It also crosses the placental membranes. Concentrations in the kidney are higher than in the serum. Inhaled tobramycin produces bactericidal concentrations in the lower respiratory tract in children with cystic fibrosis. [13] Metabolism: The uptake\u00a0of tobramycin into hepatocytes is limited, and the drug is minimally metabolized in the liver."}
{"id": "article-35928_12", "title": "Tobramycin -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Tobramycin is\u00a0excreted primarily\u00a0by glomerular filtration.\u00a0The elimination half-life of tobramycin following parenteral administration is 2\u00a0to 3 hours and\u00a0varies from 50\u00a0to 70 hours in\u00a0patients with impaired renal function. [14]", "contents": "Tobramycin -- Mechanism of Action -- Pharmacokinetics. Excretion: Tobramycin is\u00a0excreted primarily\u00a0by glomerular filtration.\u00a0The elimination half-life of tobramycin following parenteral administration is 2\u00a0to 3 hours and\u00a0varies from 50\u00a0to 70 hours in\u00a0patients with impaired renal function. [14]"}
{"id": "article-35928_13", "title": "Tobramycin -- Administration", "content": "Tobramycin is administered\u00a0via IV, IM, topical and inhalational\u00a0routes.\u00a0The efflux P-glycoprotein pump located in the brush border of the intestines leads to poor bioavailability, so oral administration is avoided. [15] Tobramycin can be combined with beta-lactams, such as penicillins or cephalosporins, to penetrate the outer walls of gram-negative bacteria. [16] Clinicians can use tobramycin as a 0.3% ophthalmic solution or 0.3% ointment to treat ocular infections. [17] [18] Tobramycin administration via oral inhalation is available to treat cystic fibrosis-associated pneumonia. [6] Intramuscular injection, intravenous infusion,\u00a0and intraventricular (off-label) administration have been used to treat serious bacterial infections. [19] [20]", "contents": "Tobramycin -- Administration. Tobramycin is administered\u00a0via IV, IM, topical and inhalational\u00a0routes.\u00a0The efflux P-glycoprotein pump located in the brush border of the intestines leads to poor bioavailability, so oral administration is avoided. [15] Tobramycin can be combined with beta-lactams, such as penicillins or cephalosporins, to penetrate the outer walls of gram-negative bacteria. [16] Clinicians can use tobramycin as a 0.3% ophthalmic solution or 0.3% ointment to treat ocular infections. [17] [18] Tobramycin administration via oral inhalation is available to treat cystic fibrosis-associated pneumonia. [6] Intramuscular injection, intravenous infusion,\u00a0and intraventricular (off-label) administration have been used to treat serious bacterial infections. [19] [20]"}
{"id": "article-35928_14", "title": "Tobramycin -- Administration -- Adult Dosing", "content": "For severe infections, the dosage for tobramycin is 3 mg/kg/d in divided doses every 8 hours. If the infections are life-threatening, the dose can be increased to 5 mg/kg/d in equally divided doses every 6 to 8 hours and reduced to 3 mg/kg/d as clinically appropriate. However, dosage should not exceed 5 mg/kg/d unless serum levels are monitored to prevent potential toxicity due to excessive serum levels. According to the Infectious Diseases Society of America (IDSA) 2022 guidelines,\u00a0 a single dose of\u00a05 mg/kg\u00a0is recommended\u00a0for cystitis caused by  extended-spectrum \u03b2-lactamase\u2013producing Enterobacterales ( ESBL-E ), Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales (CRE). [21]", "contents": "Tobramycin -- Administration -- Adult Dosing. For severe infections, the dosage for tobramycin is 3 mg/kg/d in divided doses every 8 hours. If the infections are life-threatening, the dose can be increased to 5 mg/kg/d in equally divided doses every 6 to 8 hours and reduced to 3 mg/kg/d as clinically appropriate. However, dosage should not exceed 5 mg/kg/d unless serum levels are monitored to prevent potential toxicity due to excessive serum levels. According to the Infectious Diseases Society of America (IDSA) 2022 guidelines,\u00a0 a single dose of\u00a05 mg/kg\u00a0is recommended\u00a0for cystitis caused by  extended-spectrum \u03b2-lactamase\u2013producing Enterobacterales ( ESBL-E ), Pseudomonas aeruginosa, and carbapenem-resistant Enterobacterales (CRE). [21]"}
{"id": "article-35928_15", "title": "Tobramycin -- Administration -- Intravenous Administration", "content": "For intravenous administration, the usual volume of diluent (0.9% sodium chloride injection or 5% dextrose injection) is 50 to 100 mL for adult doses.\u00a0Tobramycin is usually infused for over 20 to 60 minutes. A shorter infusion period (<20 min) is not recommended as peak serum levels can exceed 12 mcg/mL, resulting in supratherapeutic concentrations. Tobramycin injection\u00a0should not be premixed with other drugs and should be administered separately according to the recommended dose and route. The usual treatment duration is 7\u00a0to 10 days.", "contents": "Tobramycin -- Administration -- Intravenous Administration. For intravenous administration, the usual volume of diluent (0.9% sodium chloride injection or 5% dextrose injection) is 50 to 100 mL for adult doses.\u00a0Tobramycin is usually infused for over 20 to 60 minutes. A shorter infusion period (<20 min) is not recommended as peak serum levels can exceed 12 mcg/mL, resulting in supratherapeutic concentrations. Tobramycin injection\u00a0should not be premixed with other drugs and should be administered separately according to the recommended dose and route. The usual treatment duration is 7\u00a0to 10 days."}
{"id": "article-35928_16", "title": "Tobramycin -- Administration -- Inhalation Solution", "content": "Tobramycin, 300 mg/5 mL solution, is administered by oral inhalation for 15 minutes using a nebulizer in patients with cystic fibrosis. The recommended dose of tobramycin inhalation solution for pediatric patients\u00a06 years of age and older and adults is\u00a01 single-dose ampule (300 mg) inhaled twice daily for 28 days. Dosage need not be adjusted by weight. Tobramycin inhalation solution after 28 days of treatment should be stopped for the next 28 days and then resume for the next 28 days. The doses should be inhaled as close to 12 hours apart as possible;\u00a0doses should not be taken less than 6 hours apart.", "contents": "Tobramycin -- Administration -- Inhalation Solution. Tobramycin, 300 mg/5 mL solution, is administered by oral inhalation for 15 minutes using a nebulizer in patients with cystic fibrosis. The recommended dose of tobramycin inhalation solution for pediatric patients\u00a06 years of age and older and adults is\u00a01 single-dose ampule (300 mg) inhaled twice daily for 28 days. Dosage need not be adjusted by weight. Tobramycin inhalation solution after 28 days of treatment should be stopped for the next 28 days and then resume for the next 28 days. The doses should be inhaled as close to 12 hours apart as possible;\u00a0doses should not be taken less than 6 hours apart."}
{"id": "article-35928_17", "title": "Tobramycin -- Administration -- Inhalation Solution", "content": "Tobramycin should not be diluted or mixed with any other medication or dornase alfa in the nebulizer. Tobramycin inhalation solution\u00a0should not be used for\u00a0subcutaneous, intravenous, or intrathecal administration. The drug should be used cautiously\u00a0in premature neonates, as\u00a0renal immaturity can prolong the serum half-life of other medications.", "contents": "Tobramycin -- Administration -- Inhalation Solution. Tobramycin should not be diluted or mixed with any other medication or dornase alfa in the nebulizer. Tobramycin inhalation solution\u00a0should not be used for\u00a0subcutaneous, intravenous, or intrathecal administration. The drug should be used cautiously\u00a0in premature neonates, as\u00a0renal immaturity can prolong the serum half-life of other medications."}
{"id": "article-35928_18", "title": "Tobramycin -- Administration -- Specific Patient Population", "content": "Hepatic impairment: Tobramycin does\u00a0not undergo clinically significant hepatic metabolism. No dose adjustment is generally required.", "contents": "Tobramycin -- Administration -- Specific Patient Population. Hepatic impairment: Tobramycin does\u00a0not undergo clinically significant hepatic metabolism. No dose adjustment is generally required."}
{"id": "article-35928_19", "title": "Tobramycin -- Administration -- Specific Patient Population", "content": "Renal impairment: Serum tobramycin concentrations should be monitored during therapy\u00a0for dose adjustment. A tobramycin loading dose of 1 mg/kg is followed by subsequent dose adjustments based on the patient's serum creatinine or creatinine clearance. The half-life of tobramycin increases as the creatinine clearance of the patient decreases. Therefore, either normal doses are given at prolonged intervals or reduced doses are administered at 8-hour intervals. However, therapeutic drug monitoring is recommended. Consider monitoring patients' clinical and laboratory parameters for better therapeutic efficacy.\u00a0The clinical evidence\u00a0suggests the dosing of\u00a0tobramycin following hemodialysis sessions. [22]", "contents": "Tobramycin -- Administration -- Specific Patient Population. Renal impairment: Serum tobramycin concentrations should be monitored during therapy\u00a0for dose adjustment. A tobramycin loading dose of 1 mg/kg is followed by subsequent dose adjustments based on the patient's serum creatinine or creatinine clearance. The half-life of tobramycin increases as the creatinine clearance of the patient decreases. Therefore, either normal doses are given at prolonged intervals or reduced doses are administered at 8-hour intervals. However, therapeutic drug monitoring is recommended. Consider monitoring patients' clinical and laboratory parameters for better therapeutic efficacy.\u00a0The clinical evidence\u00a0suggests the dosing of\u00a0tobramycin following hemodialysis sessions. [22]"}
{"id": "article-35928_20", "title": "Tobramycin -- Administration -- Specific Patient Population", "content": "Pregnancy considerations:\u00a0Tobramycin is an FDA pregnancy category D medication. Aminoglycosides may cause fetal harm when\u00a0administered to a pregnant woman. Aminoglycoside antibiotics can cross the placenta, and there have been reported cases of irreversible bilateral congenital deafness in children when streptomycin was administered to the mother during pregnancy. There have been no reports of serious adverse effects on pregnant women, fetuses, or newborns with maternal use of other aminoglycosides. Use with caution only if potential benefits overweight potential risks. Tobramycin can be considered an alternative agent in cesarean section, although it is generally less preferred than other antibiotics. [23]", "contents": "Tobramycin -- Administration -- Specific Patient Population. Pregnancy considerations:\u00a0Tobramycin is an FDA pregnancy category D medication. Aminoglycosides may cause fetal harm when\u00a0administered to a pregnant woman. Aminoglycoside antibiotics can cross the placenta, and there have been reported cases of irreversible bilateral congenital deafness in children when streptomycin was administered to the mother during pregnancy. There have been no reports of serious adverse effects on pregnant women, fetuses, or newborns with maternal use of other aminoglycosides. Use with caution only if potential benefits overweight potential risks. Tobramycin can be considered an alternative agent in cesarean section, although it is generally less preferred than other antibiotics. [23]"}
{"id": "article-35928_21", "title": "Tobramycin -- Administration -- Specific Patient Population", "content": "Breastfeeding considerations:\u00a0Tobramycin is poorly excreted into breast milk, and the amount transferred to infants through breastfeeding is expected to be minimal. Older infants are likely to absorb even less tobramycin, reducing the risk of systemic adverse effects. However, monitor the infant for possible diarrhea, candidiasis, and CDAD. Inhaled tobramycin is compatible with breastfeeding. Maternal use of a\u00a0tobramycin ear\u00a0or eye drops\u00a0poses an insignificant risk for the infant. [24]", "contents": "Tobramycin -- Administration -- Specific Patient Population. Breastfeeding considerations:\u00a0Tobramycin is poorly excreted into breast milk, and the amount transferred to infants through breastfeeding is expected to be minimal. Older infants are likely to absorb even less tobramycin, reducing the risk of systemic adverse effects. However, monitor the infant for possible diarrhea, candidiasis, and CDAD. Inhaled tobramycin is compatible with breastfeeding. Maternal use of a\u00a0tobramycin ear\u00a0or eye drops\u00a0poses an insignificant risk for the infant. [24]"}
{"id": "article-35928_22", "title": "Tobramycin -- Administration -- Specific Patient Population", "content": "Pediatric patients: Tobramycin can be administered up to\u00a04 mg/kg/d during early neonatal periods. Weight-based dosing is recommended in pediatric patients. Therapy duration should be limited to 7\u00a0to 10 days to prevent neurotoxicity. Older patients: Meta-analysis has implied\u00a0that elderly patients are at a higher risk for acute kidney injury due to aminoglycosides. Use with caution. [25]", "contents": "Tobramycin -- Administration -- Specific Patient Population. Pediatric patients: Tobramycin can be administered up to\u00a04 mg/kg/d during early neonatal periods. Weight-based dosing is recommended in pediatric patients. Therapy duration should be limited to 7\u00a0to 10 days to prevent neurotoxicity. Older patients: Meta-analysis has implied\u00a0that elderly patients are at a higher risk for acute kidney injury due to aminoglycosides. Use with caution. [25]"}
{"id": "article-35928_23", "title": "Tobramycin -- Adverse Effects", "content": "The overall structure of rRNA is conserved across different species; however, aminoglycosides exhibit a significantly higher affinity, approximately 10-fold, for the rRNA of prokaryotes compared to eukaryotes. This increased binding affinity is not\u00a0significant enough to explain the\u00a0adverse effect profile of tobramycin. The most common adverse effects are dizziness, headache, confusion, nausea, and skin rash.\u00a0Serious adverse drug reactions of tobramycin include ototoxicity, neuropathy, and nephrotoxicity. Rare cases of liver injury have been reported with the use of tobramycin. [26]", "contents": "Tobramycin -- Adverse Effects. The overall structure of rRNA is conserved across different species; however, aminoglycosides exhibit a significantly higher affinity, approximately 10-fold, for the rRNA of prokaryotes compared to eukaryotes. This increased binding affinity is not\u00a0significant enough to explain the\u00a0adverse effect profile of tobramycin. The most common adverse effects are dizziness, headache, confusion, nausea, and skin rash.\u00a0Serious adverse drug reactions of tobramycin include ototoxicity, neuropathy, and nephrotoxicity. Rare cases of liver injury have been reported with the use of tobramycin. [26]"}
{"id": "article-35928_24", "title": "Tobramycin -- Adverse Effects -- Resistance", "content": "Resistance to aminoglycosides occurs, as with any group of antibiotics; however, resistance occurs far less frequently than with other classes of antibiotics.\u00a0There are different explanations for this finding, such as aminoglycosides are not prescribed as readily as other classes of antibiotics, like beta-lactams.\u00a0Resistance to aminoglycosides includes modification of the target site. Three classes of enzymes that modify and decrease the efficacy of tobramycin include aminoglycoside phosphotransferases (APHs), nucleotidyltransferases (ANTs), and acetyltransferases (AACs). [2]", "contents": "Tobramycin -- Adverse Effects -- Resistance. Resistance to aminoglycosides occurs, as with any group of antibiotics; however, resistance occurs far less frequently than with other classes of antibiotics.\u00a0There are different explanations for this finding, such as aminoglycosides are not prescribed as readily as other classes of antibiotics, like beta-lactams.\u00a0Resistance to aminoglycosides includes modification of the target site. Three classes of enzymes that modify and decrease the efficacy of tobramycin include aminoglycoside phosphotransferases (APHs), nucleotidyltransferases (ANTs), and acetyltransferases (AACs). [2]"}
{"id": "article-35928_25", "title": "Tobramycin -- Adverse Effects -- Resistance", "content": "Bacteria with biofilm have greater resistance to aminoglycosides. Another mechanism of resistance to aminoglycosides is related to the reversible down-regulation of drug uptake into the bacteria. [27] Some strains of Pseudomonas aeruginosa have developed aminoglycoside resistance through enzyme modification and decreased outer membrane permeability for the drug. [28]", "contents": "Tobramycin -- Adverse Effects -- Resistance. Bacteria with biofilm have greater resistance to aminoglycosides. Another mechanism of resistance to aminoglycosides is related to the reversible down-regulation of drug uptake into the bacteria. [27] Some strains of Pseudomonas aeruginosa have developed aminoglycoside resistance through enzyme modification and decreased outer membrane permeability for the drug. [28]"}
{"id": "article-35928_26", "title": "Tobramycin -- Adverse Effects -- Drug-Drug Interactions", "content": "Concurrent use of other nephrotoxic and neurotoxic antibiotics, especially other aminoglycosides (eg, streptomycin, amikacin, kanamycin, neomycin, paromomycin, and gentamicin), cephaloridine, polymyxin B, viomycin, colistin, vancomycin, and cisplatin should be avoided. [29] [30]", "contents": "Tobramycin -- Adverse Effects -- Drug-Drug Interactions. Concurrent use of other nephrotoxic and neurotoxic antibiotics, especially other aminoglycosides (eg, streptomycin, amikacin, kanamycin, neomycin, paromomycin, and gentamicin), cephaloridine, polymyxin B, viomycin, colistin, vancomycin, and cisplatin should be avoided. [29] [30]"}
{"id": "article-35928_27", "title": "Tobramycin -- Adverse Effects -- Drug-Drug Interactions", "content": "Concurrent use of aminoglycosides with potent diuretics, such as furosemide and ethacrynic acid, should be avoided. [31] Intravenously administered loop diuretics increase the risk of ototoxicity\u00a0associated with aminoglycosides. [32] Administration of intravesical BCG should be avoided with tobramycin, as antibiotics can diminish the therapeutic efficacy of intravesical BCG. [33]", "contents": "Tobramycin -- Adverse Effects -- Drug-Drug Interactions. Concurrent use of aminoglycosides with potent diuretics, such as furosemide and ethacrynic acid, should be avoided. [31] Intravenously administered loop diuretics increase the risk of ototoxicity\u00a0associated with aminoglycosides. [32] Administration of intravesical BCG should be avoided with tobramycin, as antibiotics can diminish the therapeutic efficacy of intravesical BCG. [33]"}
{"id": "article-35928_28", "title": "Tobramycin -- Contraindications", "content": "Contraindications include patients with hypersensitivity to tobramycin or any other aminoglycoside antibiotics. In addition, caution is necessary for elderly patients, those prone to dehydration, and those with preexisting conditions,\u00a0including renal failure, neuromuscular conditions like myasthenia gravis, and Parkinson disease.", "contents": "Tobramycin -- Contraindications. Contraindications include patients with hypersensitivity to tobramycin or any other aminoglycoside antibiotics. In addition, caution is necessary for elderly patients, those prone to dehydration, and those with preexisting conditions,\u00a0including renal failure, neuromuscular conditions like myasthenia gravis, and Parkinson disease."}
{"id": "article-35928_29", "title": "Tobramycin -- Contraindications", "content": "Clostridium difficile \u2013associated diarrhea (CDAD) is reported with tobramycin injection and may range from mild diarrhea to fatal colitis. Careful consideration of the patient's medical history is essential, as cases of CDAD have been reported to occur more than 2 months after antibiotic administration.\u00a0If CDAD is suspected or confirmed, it may be necessary to discontinue ongoing tobramycin use. Close monitoring and appropriate management should be initiated in such cases. [34]", "contents": "Tobramycin -- Contraindications. Clostridium difficile \u2013associated diarrhea (CDAD) is reported with tobramycin injection and may range from mild diarrhea to fatal colitis. Careful consideration of the patient's medical history is essential, as cases of CDAD have been reported to occur more than 2 months after antibiotic administration.\u00a0If CDAD is suspected or confirmed, it may be necessary to discontinue ongoing tobramycin use. Close monitoring and appropriate management should be initiated in such cases. [34]"}
{"id": "article-35928_30", "title": "Tobramycin -- Contraindications", "content": "Tobramycin injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid tobramycin formulations\u00a0containing sodium metabisulfite in patients with documented\u00a0hypersensitivity. [35]", "contents": "Tobramycin -- Contraindications. Tobramycin injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid tobramycin formulations\u00a0containing sodium metabisulfite in patients with documented\u00a0hypersensitivity. [35]"}
{"id": "article-35928_31", "title": "Tobramycin -- Monitoring", "content": "Monitoring drug frequency and dosing is essential in tobramycin administration to decrease the chances of adverse effects. Researchers have observed that a longer dosing interval may reduce the risk of ototoxicity and nephrotoxicity. [3] The dosing and frequency of administration require adjustment based on the patient\u2019s renal function because the medication is retained longer in patients with renal abnormalities or renal failure. [26]", "contents": "Tobramycin -- Monitoring. Monitoring drug frequency and dosing is essential in tobramycin administration to decrease the chances of adverse effects. Researchers have observed that a longer dosing interval may reduce the risk of ototoxicity and nephrotoxicity. [3] The dosing and frequency of administration require adjustment based on the patient\u2019s renal function because the medication is retained longer in patients with renal abnormalities or renal failure. [26]"}
{"id": "article-35928_32", "title": "Tobramycin -- Monitoring", "content": "The drug is excreted mainly by the kidneys, so it is essential to monitor renal function. [36] Tobramycin can cross the placenta,\u00a0accumulating in the kidney and urine of the fetus. [12] The hypothesis is that tobramycin could potentially cause nephrotoxic events in the fetus, but this requires further investigation. [37]", "contents": "Tobramycin -- Monitoring. The drug is excreted mainly by the kidneys, so it is essential to monitor renal function. [36] Tobramycin can cross the placenta,\u00a0accumulating in the kidney and urine of the fetus. [12] The hypothesis is that tobramycin could potentially cause nephrotoxic events in the fetus, but this requires further investigation. [37]"}
{"id": "article-35928_33", "title": "Tobramycin -- Monitoring", "content": "Serum sodium, calcium, and magnesium should be monitored while on treatment. Peak and trough tobramycin serum levels should be monitored periodically, usually after the first 2 to 3 doses. The dosage can be adjusted if needed and monitored at every 3- to 4-day intervals during therapy. Prolonged serum concentrations higher than 12 mcg/mL should be avoided. Rising trough concentrations above 2 mcg/mL might indicate tissue accumulation. Monitor serum levels closely in patients with advanced age and known renal impairment. Therapeutic drug monitoring is essential in patients receiving aminoglycosides, including tobramycin. [38]", "contents": "Tobramycin -- Monitoring. Serum sodium, calcium, and magnesium should be monitored while on treatment. Peak and trough tobramycin serum levels should be monitored periodically, usually after the first 2 to 3 doses. The dosage can be adjusted if needed and monitored at every 3- to 4-day intervals during therapy. Prolonged serum concentrations higher than 12 mcg/mL should be avoided. Rising trough concentrations above 2 mcg/mL might indicate tissue accumulation. Monitor serum levels closely in patients with advanced age and known renal impairment. Therapeutic drug monitoring is essential in patients receiving aminoglycosides, including tobramycin. [38]"}
{"id": "article-35928_34", "title": "Tobramycin -- Toxicity", "content": "FDA-boxed warnings for tobramycin are ototoxicity, nephrotoxicity, and neuromuscular blockage. [39] These adverse reactions limit the use of this class of broad-spectrum bactericidal antibiotics.", "contents": "Tobramycin -- Toxicity. FDA-boxed warnings for tobramycin are ototoxicity, nephrotoxicity, and neuromuscular blockage. [39] These adverse reactions limit the use of this class of broad-spectrum bactericidal antibiotics."}
{"id": "article-35928_35", "title": "Tobramycin -- Toxicity -- Ototoxicity", "content": "Ototoxicity occurs from the loss of hair cells in the inner ear. [40] The damage to cranial nerve VIII (vestibulocochlear nerve) could\u00a0cause hearing or balance dysfunctions.\u00a0Once-daily administration of tobramycin is thought to help reduce the risk of cytotoxicity. This adverse effect is often irreversible. [3]", "contents": "Tobramycin -- Toxicity -- Ototoxicity. Ototoxicity occurs from the loss of hair cells in the inner ear. [40] The damage to cranial nerve VIII (vestibulocochlear nerve) could\u00a0cause hearing or balance dysfunctions.\u00a0Once-daily administration of tobramycin is thought to help reduce the risk of cytotoxicity. This adverse effect is often irreversible. [3]"}
{"id": "article-35928_36", "title": "Tobramycin -- Toxicity -- Nephrotoxicity", "content": "Nephrotoxicity, unlike ototoxicity, is a reversible adverse reaction.\u00a0In a double-blind study completed at Johns Hopkins University School of Medicine, researchers noted that aminoglycoside-induced ototoxicity and nephrotoxicity occurred independently. [41]", "contents": "Tobramycin -- Toxicity -- Nephrotoxicity. Nephrotoxicity, unlike ototoxicity, is a reversible adverse reaction.\u00a0In a double-blind study completed at Johns Hopkins University School of Medicine, researchers noted that aminoglycoside-induced ototoxicity and nephrotoxicity occurred independently. [41]"}
{"id": "article-35928_37", "title": "Tobramycin -- Toxicity -- Nephrotoxicity", "content": "As with\u00a0preventing ototoxicity, nephrotoxicity is avoidable by longer dosing intervals.\u00a0Tobramycin can cause both direct nephrotoxicity (dose-related) and hypersensitivity reactions.\u00a0Tobramycin activates the renin-angiotensin-aldosterone system and can cause permanent vasoconstriction in the kidneys,\u00a0resulting in an oliguric state with minimal urine output.\u00a0The toxic changes caused by tobramycin are observable in the proximal tubule. Vacuolation and myeloid bodies can be observed in the tubular epithelial cell lysosomes under electron microscopy. Granular casts, microscopic hematuria, and proteinuria are also often present. [42]", "contents": "Tobramycin -- Toxicity -- Nephrotoxicity. As with\u00a0preventing ototoxicity, nephrotoxicity is avoidable by longer dosing intervals.\u00a0Tobramycin can cause both direct nephrotoxicity (dose-related) and hypersensitivity reactions.\u00a0Tobramycin activates the renin-angiotensin-aldosterone system and can cause permanent vasoconstriction in the kidneys,\u00a0resulting in an oliguric state with minimal urine output.\u00a0The toxic changes caused by tobramycin are observable in the proximal tubule. Vacuolation and myeloid bodies can be observed in the tubular epithelial cell lysosomes under electron microscopy. Granular casts, microscopic hematuria, and proteinuria are also often present. [42]"}
{"id": "article-35928_38", "title": "Tobramycin -- Toxicity -- Nephrotoxicity", "content": "Close\u00a0monitoring of kidney function\u00a0is crucial to minimize nephrotoxic effects. [36] Maintaining adequate hydration can also decrease the likelihood of nephrotoxic events. Studies show that antioxidant administration, most notably with deferoxamine, can alleviate the toxic\u00a0effects\u00a0observed in the kidneys. [43]", "contents": "Tobramycin -- Toxicity -- Nephrotoxicity. Close\u00a0monitoring of kidney function\u00a0is crucial to minimize nephrotoxic effects. [36] Maintaining adequate hydration can also decrease the likelihood of nephrotoxic events. Studies show that antioxidant administration, most notably with deferoxamine, can alleviate the toxic\u00a0effects\u00a0observed in the kidneys. [43]"}
{"id": "article-35928_39", "title": "Tobramycin -- Toxicity -- Neurotoxicity", "content": "Tobramycin causes neuromuscular blockade by interfering with acetylcholine release.\u00a0Patients with diseases affecting the neuromuscular junction, such as myasthenia gravis (MG), should not take aminoglycosides. This group of antibiotics can trigger or exacerbate symptoms of MG.\u00a0If a patient with MG starts to deteriorate after tobramycin therapy, it is best to discontinue or reduce the dosage. [44] Aminoglycosides also cause drug-induced myasthenic syndrome, a reversible disorder in patients who otherwise\u00a0do\u00a0not have neuromuscular transmission defects.\u00a0The symptoms of the drug-induced myasthenic syndrome will occur soon after\u00a0initiating therapy\u00a0but will cease upon\u00a0discontinuing the medication. [45]", "contents": "Tobramycin -- Toxicity -- Neurotoxicity. Tobramycin causes neuromuscular blockade by interfering with acetylcholine release.\u00a0Patients with diseases affecting the neuromuscular junction, such as myasthenia gravis (MG), should not take aminoglycosides. This group of antibiotics can trigger or exacerbate symptoms of MG.\u00a0If a patient with MG starts to deteriorate after tobramycin therapy, it is best to discontinue or reduce the dosage. [44] Aminoglycosides also cause drug-induced myasthenic syndrome, a reversible disorder in patients who otherwise\u00a0do\u00a0not have neuromuscular transmission defects.\u00a0The symptoms of the drug-induced myasthenic syndrome will occur soon after\u00a0initiating therapy\u00a0but will cease upon\u00a0discontinuing the medication. [45]"}
{"id": "article-35928_40", "title": "Tobramycin -- Toxicity -- Overdose", "content": "Patients overdosed on tobramycin with normal renal function should be hydrated adequately to preserve urine output of 3\u00a0to 5 mL/kg/h. Fluid and electrolyte balance, creatinine clearance, and tobramycin serum concentrations should be monitored closely until the serum tobramycin concentration falls below\u00a02 mcg/mL. Patients with a tobramycin elimination half-life exceeding 2 hours or impaired renal function may require aggressive therapy, including the potential benefit of hemodialysis. It is crucial to note that inhaled tobramycin can cause systemic toxicity in patients with renal dysfunction. [46]", "contents": "Tobramycin -- Toxicity -- Overdose. Patients overdosed on tobramycin with normal renal function should be hydrated adequately to preserve urine output of 3\u00a0to 5 mL/kg/h. Fluid and electrolyte balance, creatinine clearance, and tobramycin serum concentrations should be monitored closely until the serum tobramycin concentration falls below\u00a02 mcg/mL. Patients with a tobramycin elimination half-life exceeding 2 hours or impaired renal function may require aggressive therapy, including the potential benefit of hemodialysis. It is crucial to note that inhaled tobramycin can cause systemic toxicity in patients with renal dysfunction. [46]"}
{"id": "article-35928_41", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "Tobramycin is a potent and effective aminoglycoside antibiotic approved for treating complicated infections with\u00a0various indications. Due to its weak binding affinity to the rRNA of eukaryotes,\u00a0the drug can cause serious\u00a0adverse events in patients. [2] The clinical team must monitor the patient for\u00a0adverse effects and intervene promptly. Proper patient education regarding the potential negative effects of tobramycin, coupled with diligent monitoring, can play a crucial role in preventing adverse outcomes.", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. Tobramycin is a potent and effective aminoglycoside antibiotic approved for treating complicated infections with\u00a0various indications. Due to its weak binding affinity to the rRNA of eukaryotes,\u00a0the drug can cause serious\u00a0adverse events in patients. [2] The clinical team must monitor the patient for\u00a0adverse effects and intervene promptly. Proper patient education regarding the potential negative effects of tobramycin, coupled with diligent monitoring, can play a crucial role in preventing adverse outcomes."}
{"id": "article-35928_42", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "Active participation and coordination among interprofessional healthcare team members, including clinicians and pharmacists, are essential to minimize adverse events and facilitate early detection. Implementing preventative measures to mitigate the risk of toxic adverse effects is paramount. This includes regularly assessing a patient's renal function and ensuring adequate hydration, which can help prevent acute kidney injury. The ordering clinician should collaborate with the pharmacy department to obtain dosing information, evaluate potential drug interactions, and gather tobramycin-specific antimicrobial spectrum data. The clinical nursing staff\u00a0is responsible for administering the medication, closely monitoring for any adverse events, and assessing the effectiveness of the treatment. Effective communication and collaboration among the healthcare team members will ensure that any issues or concerns are promptly addressed and reported to the clinicians. This interprofessional coordination not only improves patient outcomes but also helps minimize adverse events associated with tobramycin therapy.", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. Active participation and coordination among interprofessional healthcare team members, including clinicians and pharmacists, are essential to minimize adverse events and facilitate early detection. Implementing preventative measures to mitigate the risk of toxic adverse effects is paramount. This includes regularly assessing a patient's renal function and ensuring adequate hydration, which can help prevent acute kidney injury. The ordering clinician should collaborate with the pharmacy department to obtain dosing information, evaluate potential drug interactions, and gather tobramycin-specific antimicrobial spectrum data. The clinical nursing staff\u00a0is responsible for administering the medication, closely monitoring for any adverse events, and assessing the effectiveness of the treatment. Effective communication and collaboration among the healthcare team members will ensure that any issues or concerns are promptly addressed and reported to the clinicians. This interprofessional coordination not only improves patient outcomes but also helps minimize adverse events associated with tobramycin therapy."}
{"id": "article-35928_43", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "In the face of rising antibiotic resistance, the healthcare team must exercise judicious prescribing practices regarding tobramycin. The appropriate and limited use of tobramycin ensures its continued efficacy in the community.", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. In the face of rising antibiotic resistance, the healthcare team must exercise judicious prescribing practices regarding tobramycin. The appropriate and limited use of tobramycin ensures its continued efficacy in the community."}
{"id": "article-35928_44", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "To ensure appropriate prescribing practices, involving a board-certified infectious disease pharmacist with access to the latest antibiogram data is beneficial. Their expertise can help guide the selection and optimal use of tobramycin based on local resistance patterns. This is a vital aspect of antibiotic stewardship, emphasizing responsible antibiotic use.", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. To ensure appropriate prescribing practices, involving a board-certified infectious disease pharmacist with access to the latest antibiogram data is beneficial. Their expertise can help guide the selection and optimal use of tobramycin based on local resistance patterns. This is a vital aspect of antibiotic stewardship, emphasizing responsible antibiotic use."}
{"id": "article-35928_45", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "The antibiotic stewardship program necessitates open communication and feedback among healthcare professionals, including medical microbiologists, infectious disease specialists, pharmacists, and infection prevention and control teams. Collaborative efforts in monitoring and optimizing antibiotic use can help combat antibiotic resistance and enhance patient care.", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. The antibiotic stewardship program necessitates open communication and feedback among healthcare professionals, including medical microbiologists, infectious disease specialists, pharmacists, and infection prevention and control teams. Collaborative efforts in monitoring and optimizing antibiotic use can help combat antibiotic resistance and enhance patient care."}
{"id": "article-35928_46", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "By implementing these strategies, the healthcare team can contribute to preserving the effectiveness of tobramycin and other antibiotics, ensuring their continued efficacy in treating infections and improving patient outcomes. [47]", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. By implementing these strategies, the healthcare team can contribute to preserving the effectiveness of tobramycin and other antibiotics, ensuring their continued efficacy in treating infections and improving patient outcomes. [47]"}
{"id": "article-35928_47", "title": "Tobramycin -- Enhancing Healthcare Team Outcomes", "content": "Caution is required when prescribing tobramycin to patients with neuromuscular junction disorders due to its potential to decrease acetylcholine. However, in complicated systemic infections, the interprofessional team can assess risks and benefits to consider tobramycin as a valuable treatment option.\u00a0[Level 5]", "contents": "Tobramycin -- Enhancing Healthcare Team Outcomes. Caution is required when prescribing tobramycin to patients with neuromuscular junction disorders due to its potential to decrease acetylcholine. However, in complicated systemic infections, the interprofessional team can assess risks and benefits to consider tobramycin as a valuable treatment option.\u00a0[Level 5]"}
{"id": "article-35928_48", "title": "Tobramycin -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Tobramycin -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}